Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
Portfolio Pulse from Vandana Singh
Sanofi's investigational drug tolebrutinib showed mixed results in phase 3 trials for multiple sclerosis. While it met the primary endpoint in the HERCULES study for non-relapsing secondary progressive multiple sclerosis, it failed in the GEMINI studies for relapsing forms. Despite concerns over liver safety and effectiveness, analysts see a potential $1-2 billion opportunity.
September 03, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's tolebrutinib showed mixed results in phase 3 trials, meeting the primary endpoint in one study but failing in others. Despite safety concerns, analysts see a potential $1-2 billion opportunity.
Sanofi's tolebrutinib met the primary endpoint in the HERCULES study, which is positive news. However, it failed in the GEMINI studies, raising concerns about its effectiveness. Despite this, analysts see a significant market opportunity, which has positively impacted the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100